Notice/News
Notice/News
Number
Title
Date
1
[Finance Economy Plus] “Patents are the sword; royalties are the shield” — ToolGen declares 2026 its inaugural year for monetizing gene‑editing “scissors.”
2026.02.18
2
[Press Release] ToolGen Enters 'Harvest Season' for Global IP Monetization ; Appoints Litigation & Negotiation Expert Dave Koo as CLO
2026.02.12
3
[Notice] CRISPR RNP Patent Status update(US,EU)
2026.02.04
4
[Biz watch] ToolGen Speeds Up in H1 Amid 10‑Year Patent Dispute
2026.01.27
5
[BIO Insight] ToolGen, Confident in Patent Battle Win: ‘We’ll Commercialize Gene‑Editing IP’
2026.01.25
6
[Notice] ToolGen Secures Decision to Resume CRISPR-Cas9 Interference Proceedings as Senior Party
2026.01.21
7
[Notice] Frequently Asked Questions (FAQ)
2026.01.15
8
[MoneyToday] MoneyToday Power Interview
2025.12.26
9
[Notice] CRISPR RNP Patent Status(US,EU)
2025.12.24
10
[Press Release] ToolGen Receives Intention to Grant for European ‘CRISPR RNP’ Patent… Vertex’s Attempt to Block Overturned
2025.12.10
11
[Press Release] ToolGen Successfully Defends European CRISPR RNP Plant Patent… “An Unprecedented Outcome Overturning Preliminary Decision”
2025.12.03
12
[Press Release] ToolGen and GenEditBio Sign Strategic Cross-License Agreement… Accelerating Co-Development of Innovative Gene-Editing Therapies
2025.11.24
13
[Overseas Press Release ] ToolGen and GenEditBio Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics
2025.11.24
14
[NATV] Policy Seminar on Securing Growth Drivers for the Advanced Bio Industry
2025.11.21
15
[Press Release] ToolGen Completes U.S. Patent Registration for CRISPR Cas9 RNP Core Technology… Files U.S. Lawsuit Related to CASGEVY®
2025.11.19